| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Leukemia | |||||
| Lymphoma | |||||
| 2 | More general conditions related to this trial | ||||
| Immune System Diseases | |||||
| Immunoproliferative Disorders | |||||
| Lymphatic Diseases | |||||
| Lymphoproliferative Disorders | |||||
| Neoplasms | |||||
| Neoplasms by Histologic Type | |||||
| 3 | Interventions listed in this trial | ||||
| 7-hydroxystaurosporine | |||||
| fludarabine phosphate | |||||
| 4 | Additional drug interventions recognized in this trial | ||||
| Fludarabine | |||||
| Fludarabine monophosphate | |||||
| Staurosporine | |||||
| 5 | More general drug interventions related to this trial | ||||
| Antimetabolites | |||||
| Antimetabolites, Antineoplastic | |||||
| Antineoplastic Agents | |||||
| Enzyme Inhibitors | |||||
| Immunologic Factors | |||||
| Immunosuppressive Agents | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Protein Kinase Inhibitors | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| NCI - Center for Cancer Research-Medical Oncology | |||||
| National Cancer Institute (NCI) | |||||
|
